Applied Genetic Technologies Corporation

Alachua, FL 32615

Market Performance

NASDAQ: AGTC
Market Cap $61.5 Million
52 Week High $3.40
52 Week Low $10.85

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $1.19MM
First Award Date 05/01/01
Most Recent Award Date 09/15/15

Key Personnel

Last Name Name Awards Contact
Walker Mark C Walker 1
Drogemuller Chris Drogemuller 1
Chulay Jeffrey D Chulay 1
Ye Guo-Jie Ye 3

6 Awards Won

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-12-089
Budget: 09/15/15 - 09/14/16

DESCRIPTION (provided by applicant): Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors. Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness, and best visual acuity under non-bright light conditions is usually 20/200 or worse and generally stab...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-12-089
Budget: 09/15/14 - 09/14/15

DESCRIPTION (provided by applicant): Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors. Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness, and best visual acuity under non-bright light conditions is usually 20/200 or worse and generally stab...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-12-089
Budget: 09/15/13 - 09/14/14

Project Summary/Abstract Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors. Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness, and best visual acuity under non-bright light conditions is usually 20/200 or worse and generally stable over time...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 06/01/10 - 05/31/11

DESCRIPTION (provided by applicant): Complete achromatopsia is an inherited retinal disorder characterized by severely reduced visual acuity, nystagmus, severe photophobia, a small central scotoma, eccentric fixation, and complete loss of color discrimination. In 50% of patients with achromatopsia the disease is caused by mutations in the cycli...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/03 - 07/31/04

DESCRIPTION (provided by applicant): We propose to develop Gene Therapy vectors that are targeted to particular cell membrane receptors, cell types and/or tissues. Development of these precise delivery systems will help overcome potential adverse reactions and high dosing requirements imposed by the current, non-targeted, traditional Gene Therap...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/01 - 10/31/02

DESCRIPTION (applicant's abstract): The innovative use of AAV vector technology is proposed to develop milestones essential for the safe treatment of anemia secondary to chronic renal failure in cats. An A.AV-FeEPO vector has been constructed. The initial, in vitro, study will determine whether this vector can ach...